The company's primary focus is on the preclinical and early clinical development of its products, which contain an anti-inflammatory corticosteroid that selectively targets the drug to the actual sites of pathology in inflammatory disorders. Enceladus operates in the fields of inflammation, autoimmune diseases, and cancer, seeking interaction with larger pharmaceutical companies for late stage development and marketing. The company has recently obtained funding enabling it to successfully complete several clinical phase IIa studies in different indications.